

Original Article

Determining the Prevalence and Detection of the Most Prevalent Virulence Genes in *Acinetobacter Baumannii* Isolated From Hospital Infections

Hassan Momtaz¹ Ph.D., Seyed Morteza Seifati² Ph.D., Marziyeh Tavakol^{1*} M.Sc.

¹Department of Microbiology, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.

²Department of Microbiology, Ashkezar Branch, Islamic Azad University, Ashkezar, Iran.

ABSTRACT

Article history

Received 11 Apr 2015

Accepted 22 May 2015

Available online 8 Aug 2015

Key words

Acinetobacter baumannii

Hospital infections

Virulence genes

Background and Aims: *Acinetobacter baumannii* is mostly a cause of septicemia, pneumonia and urinary tract infections following hospitalization of patients with more severe illnesses. The aim of this study was to determine the prevalence and detection of the most prevalent virulence genes in *A. baumannii* isolated from hospital infections of two largest hospitals of Tehran, Iran.

Materials and Methods: In this cross-sectional study, 500 clinical specimens were obtained from various types of hospital infections over a period of 6 month, consisting of blood (98 samples), phlegm (141), urine (92), pus (134) and cerebrospinal fluid (35) from patients admitted to the Payambaran and Baqiyatallah Hospitals in Tehran. The isolated organisms were identified based on colony morphology, microscopic characteristics and various biochemical tests according to some standard laboratory methods. Conventional polymerase chain reaction (PCR) was employed to confirm the identity of the isolates.

Results: *A. baumannii* was isolated from 121 (24.2%) of the 500 cultured samples. The highest isolation of *A. baumannii* was observed in blood samples while cerebrospinal fluid had the least. The isolation rate recorded for blood samples in this study was 43.87%. fimH gene was the most virulence gene detected in 74% of samples, *sfa/focDE* and *afa/draBC* genes were next highly detected genes, respectively. The lowest isolations were observed in PapG III, papC and PapG II genes.

Conclusions: High prevalence of *A. baumannii* and their virulence genes showed hospital prevalence of these bacteria, thereby causing many problems for infections control and treatment. Therefore, determining this bacterium by molecular methods and designing conservation programs for the control of different infections in parts of the hospital seems to be urgently needed.

Introduction

Genus *Acinetobacter* is comprised of a group of Gram-negative, oxidase-negative, catalase positive, non-motile, non-spore forming and strictly aerobic cocobacilli, which are widely distributed in nature [1, 2]. *Acinetobacter* genus consists of 25 validly-named species and 9 genomic species defined by genomic DNA–DNA hybridization [3]. Four species of this genus (*A. calcoaceticus*, *A. baumannii*, *A. pittii* and *A. nosocomialis*) are often referred to as *A. calcoaceticus*-*A. baumannii* complex, form a closely related group of glucose-acidifying strains which are difficult to distinguish from each other by phenotypic tests [4, 5]. *A. baumannii* is one of the six ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) bacteria of clinical importance [6]. It is recognized as an important human pathogen causing severe infections in hospitalized patients as well as deadly cases of community acquired pneumonia [7-9]. Surveillance studies have identified *A. baumannii* as the fifth cause of pneumonia, after *P. aeruginosa*, in hospitalized patients, especially in intensive care units [10]. This organism was reported to be the fifth most common pathogen involved in infections in intensive care units among 75 countries of the five continents [11]. This bacterium has also been associated with cases of septicemia, endocarditis, meningitis, skin and soft tissue infections, wound, respiratory tract and urinary tract infections [12, 13]. *A. baumannii* was a

predominant isolate from wounded soldiers serving in Iraq [14].

The emergence and global dissemination of *A. baumannii* is attributed to its characteristics such as a remarkable ability to survive desiccation and persist for prolonged periods throughout the hospital environment [15-18], high rate of nosocomial transmission [18-20], and an inherent ability to acquire antibiotic resistance genes [21,22]. Prevalence of Virulence Factors (VF) is contributed to pathogenesis in bacteria [23]. Virulence factors help bacteria to colonize on the epithelium, evade and inhibit the host's immune response through biofilm formation, and obtain nutrition from the host [24, 25]. During the past decades, new VF have been described in *Escherichia coli*. Pathogenicity-associated islands (PAI) are blocks of VF genes that provide a mechanism to coordinate horizontal transfer of VF genes between lineages, and even between species, and have emerged as characteristic of diverse pathogenic bacteria, including uropathogenic *E. coli* strains [26]. Recognized or determine VF in uropathogenic *E. coli* include diverse adhesins, as P fimbriae (pap genes), S and F1C (sfa), Drantigen family (afa/dra), type 1 fimbriae (fimH) [26, 27] and curli fibers (csg) [28]; fibronectin receptor (fbn) [29]; toxins, as cytotoxic necrotizing factor (cnf) [30]; siderophores, as yersiniabactin (fyuA) and aerobactin (iutA); invasins as IbeA; polysaccharide coatings as group II and III capsules (kpsMT); serum resistance (traT) and

colicin V production (cvaC) [31]. Some of the virulence factors identified in *A. baumannii* included fimbriae and/or capsular polysaccharide [32, 33], the polysaccharide capsule, [34], siderophores [35, 36], biofilm [37-40], Phospholipase D and Phospholipase C [41]. However, as pointed out by Cerqueira and Peleg, [42], very little information is known about the virulence factors in *A. baumannii* and identification of these factors could contribute to the development of novel therapeutic alternatives for the control of clinically relevant pathogen. Adhesive virulence factors are divided into two subgroup; Fimbrial VF which colonization is related to this subgroup: P fimbriae (pap genes), S (sfa/focDE), Dr antigen family (afa/draBC), type I fimbriae (fimH) and non-fimbrial VF: curli fibers (csgA); fibronectin receptor (fnb); polysaccharide coatings as group II capsules (kpsMT) [43].

Identification of virulence factors in *A. baumannii* is a key to fighting this pathogen so the aim of the present study was to determine the isolation rate of *A. baumannii* in human clinical samples in Tehran, Iran and to assess the *A. baumannii* isolates for genes coding for virulence factors.

Materials and Methods

Source of bacteria

In a cross-sectional study conducted over a period of 6 months (from September 2012 to March 2013), 500 clinical specimens comprised of blood (98 samples), phlegm (141), urine (92), pus (134), cerebrospinal

fluid (35) were collected from patients admitted to the Payambaran and Baqiyatallah Hospitals in Tehran. The specimens were collected by a laboratory technician, properly labeled and transferred immediately to the microbiology laboratory. Medical Ethics Committee of Islamic Azad University of Shahrekord branch approved the research. All samples were taken from volunteer patients for this research. All ethical issues were considered and this research was performed with hospitals' permission.

Isolation and identification of *A. baumannii*

Each sample was streaked on blood agar (Merck, Germany) and MacConkey agar (Merck, Germany) and incubated aerobically at 37°C for 24 hours. Non-hemolytic, opaque and creamy colonies on blood agar and non-lactose fermenting colonies on MacConkey agar were further sub-cultured on MacConkey agar and incubated for another 24 hours at 37°C to obtain pure colonies. The isolated organisms were identified based on colonial and microscopic characteristics and various biochemical tests according to standard laboratory methods [44]. Stock cultures were maintained in both agar slant and 20% sterile buffered glycerin and were kept at -70°C. Genomic DNA was extracted from the bacterial isolates using the Genomic DNA Purification Kit (Merck, Germany) method. Conventional polymerase chain reaction (PCR) was employed to confirm the identity of the isolates. The reverse and forward primers (Cinagen, Iran) and size of product as

previously published [45] were used for the detection of *A. baumannii* 16S-23S ribosomal DNA. The standard strains of *Escherichia coli* ATCC 25922 and *A. baumannii* ATCC 19606 were used for quality control purposes as the negative and positive controls respectively.

Detection of genes coding for virulence factors

Using multiplex PCR (Master Cycler Gradient, Eppendorf, Germany), the *A. baumannii* isolates were investigated for genes coding for some recognized virulence factors identified in uropathogenic *E. coli* strains. The virulence genes investigated in this study are presented

in table 1. PCR programs (temperature and volume) for detection of 16S-23S ribosomal DNA and virulence factors genes in *A. baumannii* are summarized in table 2. The PCR amplified products (10 μ L) were subjected to electrophoresis in a 1.5% agarose (Fermentas, Germany) gel in 1X TBE buffer (Fermentas, Germany) at 80V for 30 minutes stained with solution of ethidium bromide and examined under ultra violet illumination (Uvi tec, England). The 100-bp ladder (Fermentas, Germany) was used as standard for determining molecular mass of PCR products.

Table 1. Primers used for detection of virulence genes in *A. baumannii*

Gene	Primer	Primer Sequence (5'-3')	Size of product (bp)	Reference
<i>afa/draBC</i>	afa1	GCTGGGCAGCAAAGTATAACTCTC	750	27
	afa2	CATCAAGCTGTTTGTTCGTCCGCCG		
<i>cnf1</i>	cnf1	AAGATGGAGTTTCCTATGCAGGAG	498	46
	cnf2	CATTCAGAGTCCTGCCCTCATTATT		
<i>cnf2</i>	cnf2a	AATCTAATTAAGAGAAC	543	47
	cnf2b	CATGCTTTGTATATCTA		
<i>csgA</i>	M464	ACTCTGACTTGACTATTACC	200	47
	M465	AGATGCAGTCTGGTCAAC		
<i>cvaC</i>	CoIV-CF	CACACACAAACGGGAGCTGTT	680	26
	CoIV-CR	CTTCCCGCAGCATAGTTCCAT		
<i>fimH</i>	FimH F	TGCAGAACGGATAAGCCGTGG	508	26
	FimH R	GCAGTCACCTGCCCTCCGGTA		
<i>fyuA</i>	FyuA f	TGATTAACCCCGCGACGGGAA	880	[26,48]
	FyuA R	CGCAGTAGGCACGATGTTGTA		
<i>ibeA</i>	ibe10 F	AGGCAGGTGTGCGCCCGGTAC	170	[26,49]
	fibe10 R	TGGTGCTCCGGCAAACCATGC		
<i>iutA</i>	AerJ F	GGCTGGACATCATGGAACTGG	300	[50]
	AerJ R	CGTCGGGAACGGGTAGAATCG		
<i>kpsMT II</i>	kpsII F	GCGCATTGCTGATACTGTTG	272	[26]
	kpsII R	CATCCAGACGATAAGCATGAGCA		
<i>PAI</i>	RPAi F	GGACATCCTGTTACAGCGCGCA	930	[26]
	RPAi R	TCGCCACCAATCACAGCCGAAC		
<i>papC</i>	pap1	GACGGCTGTACTGCAGGGTGTGGCG	328	[27]
	pap2	ATATCCTTTCTGCAGGGATGCAATA		
<i>PapG II, III</i>	pGf	CTGTAATTACGGAAGTGATTTCTG	1070	[51]
	pGr	ACTATCCGGCTCCGGATAAACCAT		
<i>sfa/focDE</i>	sfa1	CTCCGGAGAAGTGGGTGCATCTTAC	410	[27]
	sfa2	CGGAGGAGTAATTACAAACCTGGCA		
<i>traT</i>	TraT F	GGTGTGGTGCATGAGCACAG	290	[26]
	TraT R	CACGGTTCAGCCATCCCTGAG		
<i>A. baumannii</i> detection	16S-23S	(F) CATTATCACGGTAATTAGTG	208	[45]
	ribosomal DNA	(R) AGAGCACTGTGCACTTAAG		

Table 2. PCR conditions for detection of virulence genes in *A. baumannii*

Gene	PCR program	PCR volume (50 µL)
<i>afa/draBC, cnfI, csgA, cvaC, iutA, fyuA</i>	1 cycle: 95 ^{0C} ----- 4 min. 30 cycle: 95 ^{0C} ----- 50 s 58 ^{0C} ----- 60 s 72 ^{0C} ----- 45 s 1 cycle: 72 ^{0C} ----- 8 min	5 µL PCR buffer 10X 1.5 mM MgCl ₂ 200 µM dNTP (Fermentas) 0.5 µM of each primers F & R 1.25 U Taq DNA polymerase (Fermentas) 2.5 µL DNA template
<i>cnf2, kpsMT II, PAI, papC</i>	1 cycle: 94 ^{0C} ----- 6 min. 34 cycle: 95 ^{0C} ----- 50 s 58 ^{0C} ----- 70 s 72 ^{0C} ----- 55 s 1 cycle: 72 ^{0C} ----- 10 min	5 µL PCR buffer 10X 2 mM MgCl ₂ 150 µM dNTP (Fermentas) 0.75 µM of each primers F & R 1.5 U Taq DNA polymerase (Fermentas) 3 µL DNA template
<i>fimH, ibeA, PapG II-III, sfa/focDE, traT</i>	1 cycle: 95 ^{0C} ----- 4 min. 34 cycle: 94 ^{0C} ----- 60 s 56 ^{0C} ----- 45 s 72 ^{0C} ----- 60 s 1 cycle: 72 ^{0C} ----- 10 min	5 µL PCR buffer 10X 2 mM MgCl ₂ 200 µM dNTP (Fermentas) 0.5 µM of each primers F & R 1.5 U Taq DNA polymerase (Fermentas) 5 µL DNA template
<i>16S-23S ribosomal DNA</i>	1 cycle: 94 ^{0C} ----- 6 min. 30 cycle: 95 ^{0C} ----- 60 s 58 ^{0C} ----- 60 s 72 ^{0C} ----- 40 s 1 cycle: 72 ^{0C} ----- 5 min	5 µL PCR buffer 10X 2mM MgCl ₂ 150 µM dNTP (Fermentas) 1 µM of each primers F & R 1 U Taq DNA polymerase (Fermentas) 3 µL DNA template

Statistical analysis

The data were analyzed using SPSS version 16 (SPSS Inc, Chicago, IL, USA). Chi-square and Fisher's exact tests were used to identify statistically significant relationships between the following: source of bacterial isolates and distribution of virulence genes, of the *Acinetobacter baumannii* strains isolated from

infected patients. $P < 0.05$ was considered statistically significant.

Results

Acinetobacter baumannii was isolated from 121 (24.2%) of the 500 samples cultured. The isolation rates from the various clinical samples are presented in table 3.

Table 3. Isolation rate of *A. baumannii* strains from human clinical samples

Clinical Samples	Samples (No)	<i>A. baumannii</i> (No)	Isolation rate
Blood	98	43	43.87
Phlegm	141	34	24.11
Urine	92	22	23.91
Pus	134	16	11.94
CSF	35	6	17.14
Total	500	121	24.20

Distribution of virulence genes in clinical samples in human are shown in table 4.

Table 4. Distribution of virulence genes in *A. baumannii* strains isolated from clinical samples

Sample	<i>afa/draBC</i>	<i>cnfI</i>	<i>cnf2</i>	<i>csgA</i>	<i>cvaC</i>	<i>iutA</i>	<i>fyuA</i>	<i>fimH</i>	<i>kpsMTII</i>	<i>PAI</i>	<i>ibeA</i>	<i>papC</i>	<i>PapGII</i>	<i>PapGIII</i>	<i>sfa/focDE</i>	<i>traT</i>
Blood (43)	21	16	8	9	14	17	20	38	4	5	2	1	3	2	17	4
Phlegm(34)	19	10	12	-	4	-	19	28	6	-	-	5	6	2	18	2
Urine (22)	8	3	2	4	-	3	-	20	4	8	9	1	-	-	20	6
Pus (16)	10	11	7	2	8	1	2	2	-	2	-	-	-	-	3	-
CSF (6)	2	3	2	-	-	2	-	2	3	-	4	2	1	1	4	2
Total (121)	52	43	31	15	26	23	41	90	17	15	15	9	10	5	62	14
Percent	42.97	35.53	25.61	12.39	21.48	19.00	33.88	74.38	14.04	12.39	12.39	7.43	8.26	4.13	51.23	11.57

fimH gene was the most virulence gene detected in 47% of samples and follow that *sfa/focDE* genes and *afa/draBC* respectively were high detected. Lowest isolations were on *PapG III*, *papC* and *PapG II* gens.

Discussion

Nowadays controlling infections caused by gram negative pathogen bacteria such as *A. baumannii* and appearance of resistant isolates has become a clinical challenge [43]. We tested *A. baumannii* strains, isolated from various clinical samples, for the presence of genes that codify for various virulence factors by PCR, as described for uropathogenic *E. coli*. The 24.2% isolation rate reported in the present study is higher than the 9.4% reported by Jaggi et al. [52] from various clinical samples in a tertiary care hospital in India and

the 11% reported by Siau et al. [53] in Hong Kong. The highest isolation of *A. baumannii* was observed from blood samples while cerebrospinal fluid had the least. Among the three different clinical specimens processed by Shanthi and Sekar [54], blood had the least number of *A. baumannii* isolates. The 43.87% isolation rate recorded for blood samples in this study is higher than the 23.8% reported by Jaggi et al. [52]. *A. baumannii* infections are extremely difficult to treat [55, 56] and the isolation of this organism from the various clinical specimens in this study was a cause for concern. Rahbar and Hajia [57] reported that *A. baumannii* organism is the most frequent cause of respiratory tract infections and they have isolated strains from 3-5% of patients with nosocomial pneumonia. In another study done by Rahbar et al. [58], a total of 88 strains

of *A. baumannii* were isolated from clinical specimens obtained from patients hospitalized in an Iranian 1000-bed tertiary care hospital. The majority of isolates were from respiratory tract specimens. However, in this study the highest isolation of *A. baumannii* was observed from blood samples while cerebrospinal fluid had the least. Lautenbach et al. [59] reported annual prevalence of isolates from 0% to 21% of imipenem resistance *A. baumannii* from 1989 through 2004 while moreover there were 386 patients with *A. baumannii* isolates and during the period from 2001 through 2006. Marchaim et al. [60] reported infection rate of 17% of patients in a study carried out over 42 months. Maragakis et al. [61] observed occurrences that have been traced to common-source contamination (predominantly unhygienic respiratory and ventilator equipment), and to cross-infection by the hands of health care workers caring for infected patients. The same sources of infection can be responsible for the observed prevalence in this study. Furthermore, endemicity of several strains can be a result of a single endemic strain dominating at any given period [62]. We found that *fimH* gene was the most virulence gene and follow that *sfa/focDE* and *afa/draBC* genes respectively were high detected. Adherence is related to adhesins filamentous (fimbrial structures) or non-filamentous [63]. Fimbrial structures and their participation in adhesive properties involving fibronectin were investigated by means of agglutination assays [64]. A total of 104 clinical isolates of *A. baumannii* were collected from 3 hospitals in Kermanshah

(Iran) showed they had two adhesive virulence factors of fimbriae *csgA* and *fimH* in 27 (54%) and 30 (60%) of cases, respectively [65]. Adhesive virulence factors are considered an important factor in adhesion, biofilm formation and survival of most bacteria and their virulence in human [23]. Compared to other gram-negative pathogens, relatively few virulence factors have been identified for *A. baumannii* [66]. Therefore, it can be concluded that the genes of *csgA* and *fimH* involved in forming biofilm [67, 68]. The existence of thin fimbriae in *A. baumannii* which are a major factor in adherence was described by Rosenberg *et al.* (1982) and Braun and Vidotto (2004) [33, 43].

Contrary to our study, none of Braun's isolates had relevant adhesive genes [43]. It gave that most of the samples in our study were isolated from blood, phlegm, urine, pus, cerebrospinal fluid; the difference between these two studies can be attributed to difference in the source of isolates and mechanism of adhesion in bacteria causing urinary tract infections with those of other infections. Studies show that 30% of *A. baumannii* produce capsule [69] while we did not find the relevant gene (*kpsMT*).

Conclusion

Acinetobacter baumannii was isolated from 24.2% of the samples cultured. The isolation of *A. baumannii* in this study is great concern because it is the most resistant of the genospecies and has the most clinical significance and is the mainly frequently

detected species and is usually associated with outbreaks in the hospital locale.

Conflict of Interest

The authors declare that they have no conflict of interest

Acknowledgement

References

- [1]. Abdel-El-Haleem D. Acinetobacter: environmental and biotechnological applications. *Afr J Biotechnol.* 2003; 2(4):71-75.
- [2]. Pantophlet R, Brade L, Brade H. Use of a murine O-antigen-specific monoclonal antibody to identify Acinetobacter strains of unnamed genomic species 13 Sensu Tjernberg and Ursing. *J Clin Microbiol.* 1999; 37(6):1693-698.
- [3]. Espinal P, Roca I, Vila J. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. *Future Microbiol.* 2011; 6(5):495-511.
- [4]. Nemeč A, Krizová L, Maixnerová M, van der Reijden TJ, Deschaght P, Passet V et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (Formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (Formerly Acinetobacter genomic species 13TU). *Res Microbiol.* 2011; 162(4):393-404.
- [5]. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. *J Clin Microbiol.* 1991; 29(2):277-282.
- [6]. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther.* 2013; 11(3):297-308.
- [7]. Ong CW, Lye DC, Khoo KL, Chua GS, Yeoh SF, Leo YS, et al. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. *Respirology* 2009; 14(8):1200-205.
- [8]. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. *Chest* 2006; 129(1):102-109.
- [9]. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. *J Clin Microbiol.* 2002; 40(2):685-86.
- [10]. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *Clin Infect Dis.* 2010; 51:81-87.
- [11]. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009; 302(21):2323-329.
- [12]. Dorsey CW, Beglin MS, Actis LA. Detection and analysis of iron uptake components expressed by Acinetobacter baumannii clinical isolates. *J Clin Microbiol.* 2003; 41(9):4188-193.
- [13]. Schreckenberger PC, Graevenitz A. Nonfermentative gram-negative rods. In PR Murray, Manual of Clinical Microbiology, ASM, Washington 1999:539-543.
- [14]. Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. *J Trauma* 2008; 64(2):163-68.
- [15]. Thom KA, Johnson JK, Lee MS, Harris AD. Environmental contamination because of multidrug-resistant Acinetobacter baumannii surrounding colonized or infected patients. *Am J Infect Control* 2011; 39(9):711-15.
- [16]. Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. *Am J Infect Control* 2010; 38(5):25-33.
- [17]. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. *Clin Microbiol Rev.* 2008; 21(3):538-82.
- [18]. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. As nosocomial pathogens:

The authors would like to thank Dr. M. Sarshar, at the Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, for their important technical and clinical support. This work was supported by the Islamic Azad University, Shahrekord Branch-Iran grant 92/8969.

- microbiological, clinical, and epidemiological features. *Clin Microbiol Rev.* 1996; 9(2):148-65.
- [19]. Morgan DJ, Liang SY, Smith CL, Johnson JK, Harris AD, Furuno JP. et al. Frequent multidrug-resistant *Acinetobacter baumannii* contamination of gloves, gowns, and hands of healthcare workers. *Infect Control Hosp Epidemiol.* 2010; 31(7):716-21.
- [20]. Thom KA, Harris AD, Johnson JA, Furuno JP. Low prevalence of *Acinetobacter baumannii* colonization on hospital admission. *Am J Infect Control.* 2010; 38(4):329-31.
- [21]. Roca I, Espinal P, Vila-Farrés X, Vila J. The *Acinetobacter baumannii* OxyMoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. *Front Microbiol.* 2012; 3:148.
- [22]. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother.* 2010; 65(2):233-38.
- [23]. Doughari HJ., Ndakidemi PA, Human IS, Benade S. Virulence, resistance genes and transformation amongst environmental isolates of *Escherichia coli* and *Acinetobacter* spp. *J Microbiol. Biotechnol.* 2012; 22(1): 25-33.
- [24]. Connell I, Agace W, Klemm P, Schembri M, Marild S, Svanborg C. Type 1 fimbrial expression enhances *Escherichia coli* virulence for the urinary tract. *Proc. Natl. Acad. Sci. USA* 1996; 93(18): 9827-832.
- [25]. Barnhart, M.M. and M.R. Chapman, 2006. Curli biogenesis and function. *Annu. Rev. Microbiol.*; 60: 131-147.
- [26]. Johnson JR, Stell AL. Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogenetic and host compromise. *J Infect Dis.* 2000; 181:261-72.
- [27]. Le Bouguenec CL, Archambaud M, Labigne A. A rapid and specific detection of the *pap*, *afa* and *sfa* adhesin-encoding operons in uropathogenic *Escherichia coli* strains by polymerase chain reaction. *J Clin Microbiol.* 1992; 30:1189-193.
- [28]. Gophna U, Barlev M, Seiffers R, Oelschlager TA, Hacker J, Ron EZ. Curli fibers mediate internalization of *Escherichia coli* by eukaryotic cells. *Infect Immun.* 2001; 69: 2659- 665.
- [29]. Sarén A, Virkola R, Hacker J, Korhonen TK. The cellular form of human fibronectin as an adhesion target for the S fimbriae of meningitis-associated *Escherichia coli*. *Infect Immun.* 1999; 67(5): 2671-676.
- [30]. Blanco J, Alonso MP, Gonzalez EA, Blanco M, Garabal JI. Virulence factors of bacteraemic *Escherichia coli* with particular reference to production of cytotoxic necrotizing factor (CNF) by P-fimbriated strains. *J Med Microbiol.* 1990; 31: 175-83.
- [31]. Montenegro MA, Bitter-Suermann D, Timmis JK, Agüero ME, Cabello FC, Sanyal SC, Timmis KN. Tra T gene sequences, serum resistance and pathogenicity-related factors in clinical isolates of *Escherichia coli* and other gramnegative bacteria. *J Gen Microbiol.* 1985; 131: 1511-521.
- [32]. Rosenberg M, Perry A, Bayer EA, Gutnick DL, Rosenberg E, Ofek I. Adherence of *Acinetobacter calcoaceticus* RAG-1 to human epithelial cells and to hexadecane. *Infect Immun.* 1981; 33(1):29-33.
- [33]. Rosenberg M, Bayer EA, Delarea J, Rosenberg E. Role of Thin Fimbriae in Adherence and Growth of *Acinetobacter calcoaceticus* RAG-1 on Hexadecane. *Appl Environ Microbiol* 1982; 44(4):929-37.
- [34]. Kaplan N, Rosenberg E, Jann B, Jann K. Structural studies of the capsular polysaccharide of *Acinetobacter calcoaceticus* BD4. *Eur J Biochem.* 1985; 152(2):453-58.
- [35]. Actis LA, Tolmasky ME, Crosa LM, Crosa JH. Effect of iron-limiting conditions on growth of clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol* 1993; 31(10):2812-815.
- [36]. Russo TA, Luke NR, Beanan JM, Olson R, Sauberman SL, MacDonald U, et al. The K1 capsular polysaccharide of *Acinetobacter baumannii* strain 307-0294 is a major virulence factor. *Infect Immun.* 2010; 78(9):3993-4000.
- [37]. Donlan RM. Biofilms: microbial life on surfaces. *Emerg Infect Dis.* 2002; 8(9):881-90.
- [38]. Wroblewska MM, Sawicka-Grzelak A, Marchel H, Luczak M, Sivan A. Biofilm production by clinical strains of *Acinetobacter baumannii* isolated from patients hospitalized in twotertiary care hospitals. *FEMS Immunol Med Microbiol.* 2008; 53(1):140-44.
- [39]. de Breij A, Gaddy J, van der Meer J, Koning R, Koster A, van den Broek P, et al. CsuA/BABCDE-dependent pili are not involved in the adherence of *Acinetobacter baumannii* ATCC19606(T) to human airway epithelial cells and their inflammatory response. *Res Microbiol.* 2009; 160(3):213-18.
- [40]. Gaddy JA, Actis LA. Regulation of *Acinetobacter baumannii* biofilm formation. *Future Microbiol.* 2009; 4(3):273-78.
- [41]. Antunes LC, Imperi F, Carattoli A, Visca P. Deciphering the multifactorial nature of *Acinetobacter baumannii* pathogenicity. *PLoS One* 2011; 6(8):22674.

- [42]. Cerqueira GM, Peleg AY. Insights into *Acinetobacter baumannii* pathogenicity. IUBMB Life 2011; 63(12):1055-1060.
- [43]. Braun G, Vidotto MC. Evaluation of adherence, hemagglutination and presence of genes codifying for virulence factors of *Acinetobacter baumannii* causing urinary tract infection. Mem Inst Oswaldo Cruz. 2004; 99(8): 839-44.
- [44]. Cappuccino JG, Sherman N. Microbiology Lab Manual by James G. Cappuccino and Natalie Sherman 4th edition, Benjamin-Cummings Publishing Company 1996; ISBN: 9780805305739.
- [45]. Chiang MC, Kuo SC, Chen YC, Lee YT, Chen TL, Fung CP. Polymerase chain reaction assay for the detection of *Acinetobacter baumannii* in endotracheal aspirates from patients in the intensive care unit. J Microbiol Immunol Infect. 2011; 44(2):106-10.
- [46]. Yamamoto S, Terai A, Yuri K, Kurazono H, Takeda Y, Yoshida O. Detection of urovirulence factors in *Escherichia coli* by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol. 1995; 12:85-90.
- [47]. Blanco M, Blanco JE, Blanco J. Polymerase chain reaction for detection of *Escherichia coli* strains producing cytotoxic necrotizing factor type 1 and 2 (CNF1 and CNF2). J Microbiol Meth. 1996; 26:95-101.
- [48]. Schubert S, Rakin A, Karch H, Carniel E, Hessemann J. Prevalence of the "high-pathogenicity island" of *Yersinia* species among *Escherichia coli* strains that are pathogenic to humans. Infect Immun. 1998; 66:480-85.
- [49]. Huang SH, Wass C, Fu Q, Prasadarao NV, Stins M, Kim KS. *Escherichia coli* invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene *ibe10*. Infect Immun. 1995; 63:4470-475.
- [50]. Johnson JR, Brown JJ. Colonization with and acquisition of uropathogenic *Escherichia coli* strains as revealed by polymerase chain reaction-based detection. J Infect Dis. 1998; 177:1120-124.
- [51]. Marklund BI, Tennent JM, Garcia E: Horizontal gene transfer of the *Escherichia coli* *pap* and *prs pili* operons as a mechanism for the development of tissue-specific adhesive properties. Mol Microbiol 1992; 6:2225-242.
- [52]. Jaggi N, Sissodia P, Sharma L. *Acinetobacter baumannii* isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. J Microbiol Infect Dis. 2012; 2(2):57-63.
- [53]. Siau H, Yuen KY, Wong SS, Ho PL, Luk WK: The epidemiology of acinetobacter infections in Hong Kong. J Med Microbiol 1996; 44(5):340-7.
- [54]. Shanthi M, Sekar U. Multi-drug resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* infections among hospitalized patients: risk factors and outcomes. J Assoc Physicians India 2009; 57:636, 638-40, 645.
- [55]. Beavers SF, Blossom DB, Wiemken TL, Kawaoka KY, Wong A, Goss L, et al. Comparison of risk factors for recovery of *Acinetobacter baumannii* during outbreaks at two Kentucky hospitals, 2006. Public Health Rep. 2009; 124(6):868-74.
- [56]. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, et al. Hospital outbreak caused by a carbapenem-resistant strain of *Acinetobacter baumannii*: patient prognosis and risk-factors for colonization and infection. Clin Microbiol Infect. 2005; 11(7):540-46.
- [57]. Rahbar M, Hajia M. Detection and quantitation of the etiologic agents of ventilator-associated pneumonia in endotracheal tube aspirates from patients in Iran. Infect Control Hosp Epidemiol. 2006; 27(8):884-85.
- [58]. Rahbar M, Mehrgan H, Aliakbari NH. Prevalence of antibiotic-resistant *Acinetobacter baumannii* in a 1000-bed tertiary care hospital in Tehran, Iran. Indian J Pathol Microbiol. 2010; 53(2):290-93.
- [59]. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Epidemiology and impact of imipenem resistance in *Acinetobacter baumannii*. Infect Control Hosp Epidemiol. 2009; 30(12):1186-192.
- [60]. Marchaim D, Navon-Venezia S, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, Carmeli Y. Surveillance cultures and duration of carriage of multidrug-resistant *Acinetobacter baumannii*. J Clin Microbiol 2007; 45(5):1551-555.
- [61]. Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, et al. An outbreak of multidrug-resistant *Acinetobacter baumannii* associated with pulsatile lavage wound treatment. JAMA 2004; 292(24):3006-3011.
- [62]. Villegas MV, Hartstein AI. *Acinetobacter* outbreaks, 1977-2000. Infect Control Hosp Epidemiol. 2003; 24(4):284-95.
- [63]. Hornick DB, Allen BL, Horn MA, Clegg S. Fimbrial types among respiratory isolates belonging to the family Enterobacteriaceae. J Clin Microbiol 1991; 29: 1795-800.
- [64]. Køljelg S, Vuopio-Varkila JV, Lyytikäinen O, Mikelsaar M, Wadström T. Cell surface properties of *Acinetobacter baumannii*. APMIS 1996; 104: 659-66.

- [65]. Mohajeri P, Rezaei Z, Sharbati S, Rasi H, Rostami Z, Farahani A, Khodarahmi R. Frequency of Adhesive Virulence Factors in Carbapenemase-producing *Acinetobacter baumannii* Isolated from Clinical Samples in West of Iran. *Asian J Bio Sci.* 2014; 7:158-64.
- [66]. McConnell MJ, Actis L, Pachon J. *Acinetobacter baumannii*: human infections, factors contributing to pathogenesis and animal models. *FEMS Microbiol Rev.* 2013; 37: 130-55.
- [67]. Ofek, I, Doyle RJ. *Bacterial Adhesion to Cells and Tissues.* 1st Edn. Champion and Hall, London, UK, 1994: 513-61.
- [68]. Sokurenko EV, Hasty DL, and D.E. Dykhuizen DE. Pathoadaptive mutations: Gene loss and variation in bacterial pathogens. *Trends Microbiol.* 1999;7(5):191-95.
- [69]. Joly-Guillou ML. Clinical impact and pathogenicity of *Acinetobacter*. *Clin Microbiol Infect.* 2005; 11(11): 868-73.